Arcus Biosciences, Inc. (RCUS) Q2 FY26 Earnings Call

The investment case hinges on October Castatifan data validating efficacy across RCC treatment lines.

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Call date2026-08-05
Length66 minutes
EPS$-0.72
EPS consensus$-0.98
Revenue$17.0M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q4 FY25

All RCUS earnings ยท Back to RCUS overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.